Literature DB >> 7916289

Molecular genetic haplotype segregation studies in three families with X-linked lymphoproliferative disease.

V Schuster1, S Seidenspinner, T Grimm, W Kress, S Zielen, M Bock, H W Kreth.   

Abstract

Three families with X-linked lymphoproliferative disease were studied. Affected males clinically presented with severe or fatal infectious mononucleosis, acquired hypogammaglobulinaemia, hypergammaglobulinaemia M, and malignant lymphoma including Hodgkin disease. Haplotype analysis using various DNA markers from Xq25-q27 allowed the prediction of the carrier status in females and identification of the XLP status in asymptomatic males.

Entities:  

Mesh：

Year:  1994        PMID： 7916289     DOI： 10.1007/bf01983408

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  36 in total

1.  Epstein-Barr virus-associated lymphoproliferative syndromes: studies in two European families.

Authors:  V Schuster; E Dohrmann; H W Kreth
Journal:  Cancer Detect Prev       Date:  1991

Review 2.  Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

Authors:  D W Hanto; G Frizzera; K J Gajl-Peczalska; R L Simmons
Journal:  Transplantation       Date:  1985-05       Impact factor: 4.939

Review 3.  X-linked lymphoproliferative disease.

Authors:  T A Seemayer; H Grierson; S J Pirruccello; T G Gross; D D Weisenburger; J Davis; K Spiegel; B Brichacek; J Sumegi
Journal:  Am J Dis Child       Date:  1993-11

4.  Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis.

Authors:  B E Tomkinson; R Maziarz; J L Sullivan
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

5.  Methods of detection of new families with X-linked lymphoproliferative disease.

Authors:  D T Purtilo; H L Grierson
Journal:  Cancer Genet Cytogenet       Date:  1991-02

6.  Mapping the X-linked lymphoproliferative syndrome.

Authors:  J C Skare; A Milunsky; K S Byron; J L Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro.

Authors:  D J Moss; L E Wallace; A B Rickinson; M A Epstein
Journal:  Eur J Immunol       Date:  1981-09       Impact factor: 5.532

8.  Mapping of the X-linked form of hyper-IgM syndrome (HIGM1) to Xq26 by close linkage to HPRT.

Authors:  M Padayachee; C Feighery; A Finn; C McKeown; R J Levinsky; C Kinnon; S Malcolm
Journal:  Genomics       Date:  1992-10       Impact factor: 5.736

9.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.

Authors:  D Vetrie; I Vorechovský; P Sideras; J Holland; A Davies; F Flinter; L Hammarström; C Kinnon; R Levinsky; M Bobrow
Journal:  Nature       Date:  1993-01-21       Impact factor: 49.962

10.  Physical mapping of Xq24-25 around loci closely linked to the X-linked lymphoproliferative syndrome locus: an overlapping YAC map and linkage between DXS12, DXS42, and DXS37.

Authors:  Q Wang; Y Ishikawa-Brush; A P Monaco; D L Nelson; C T Caskey; S P Pauly; G M Lenoir; B S Sylla
Journal:  Eur J Hum Genet       Date:  1993       Impact factor: 4.246
View more
  3 in total

1.  Prenatal diagnosis of X linked lymphoproliferative disease using multiplex polymerase chain reaction.

Authors:  V Schuster; S Seidenspinner; H W Kreth
Journal:  J Med Genet       Date:  1995-09       Impact factor: 6.318

2.  X-linked lymphoproliferative disease: three atypical cases.

Authors:  K Nistala; K C Gilmour; T Cranston; E G Davies; D Goldblatt; H B Gaspar; A M Jones
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

3.  Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome.

Authors:  Nicola Strnad-Trojan; Richard Linde; Janine Reichenbach; Jörg Trojan; Stefan Zeuzem; Stefan Zielen
Journal:  Eur J Pediatr       Date:  2006-02-04       Impact factor: 3.183
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.